UPDATES IN MEDICINE

2022-01-16 09:24:47 ​​ Latest Asthma and COPD Guidelines


Global Initiative for Asthma - GINA

Global Initiative for Chronic Obstructive Lung Disease - GOLD
#Guidelines #Pulmonology


Join @Updates_in_Medicine Open / Comment

2022-01-14 07:44:31 ​​ 2022 Updated living WHO guideline on drugs for covid-19


WHO’s Guideline Development Group found moderate certainty evidence that baricitinib improved survival and reduced the need for ventilation, with no observed increase in adverse effects.

The group also advises against using two other JAK inhibitors—ruxolitinib and tofacitinib—in patients with severe or critical covid-19 because evidence from small trials failed to show benefit and suggested a possible increase in serious side effects with tofacitinib.

The WHO group has also made a conditional recommendation for the use of the monoclonal antibody sotrovimab in patients with non-severe covid-19, but only in those at highest risk of hospital admission, reflecting fewer benefits in those at lower risk.


● Join @Updates_in_Medicine Open / Comment

2022-01-13 07:25:10 ​​ Duration of Covid-19 Vaccine Protection in England

A test-negative case–control study involving more than 6 million persons in England who received two doses of the ChAdOx1-S (AstraZeneca) or BNT162b2 (Pfizer) vaccine (interval, 3 to 12 weeks) showed high vaccine effectiveness against hospitalization and death from Covid-19 at 20 weeks or more after vaccination. Protection against infection waned. Waning was greater in older persons and those with underlying risk factors.


● Join @Updates_in_Medicine Open / Comment

2022-01-11 21:54:14 ​​ NEJM Evidence — A New Journal in the NEJM Group Family
(The New England Journal of Medicine)

The Editors announce the launch of NEJM Evidence, a monthly, peer-reviewed, online-only general medical journal publishing original research as well as articles focused on understanding trial design and methods, spotlighting common medical practices not supported by robust evidence, and addressing the clinical quandaries clinicians face daily.


Join @The_NEJM telegram channel to receive all the latest articles from the New England Journal of Medicine and NEJM Evidence Open / Comment

2022-01-11 05:13:11 ​​ Pig Heart Successfully Transplanted to Man

It's the first successful transplant of a genetically modified animal heart into a human, in this case a 57-year-old man with no other treatment options, said officials at the University of Maryland.


Join @Updates_in_Medicine Open / Comment

2022-01-11 03:29:47 ​​ Rapid Diagnostic Testing for SARS-CoV-2

RDTs for SARS-CoV-2 — either molecular nucleic acid amplification tests or antigen-based immunoassays to detect proteins — are approved for persons with Covid-19 symptoms and asymptomatic persons with known exposure to SARS-CoV-2 or those in a high-transmission setting. Antigen-based tests have lower sensitivity than PCR tests, but they may correlate better with replication-competent virus.


Join @Updates_in_Medicine Open / Comment

2022-01-09 06:09:53 ​​ Abortion Outcomes with Unrestricted Mifepristone

Using population-based administrative data from Ontario, investigators found that after mifepristone became available with a normal prescription, the abortion rate remained relatively stable, the proportion of abortions provided by medication increased rapidly, and adverse events and complications remained stable, as compared with the period when mifepristone was unavailable.


Join @Updates_in_Medicine Open / Comment

2022-01-06 15:14:27 ​​ Pfizer (BNT162b2) Vaccine against Covid-19 in 5-to-11-Year-Olds

After a dose for further testing was determined in a phase 1 study, a phase 2–3 trial was initiated in which two 10-μg doses of BNT162b2 were given 21 days apart to children 5 to 11 years of age. No serious adverse events were observed. High levels of neutralizing antibodies were induced, and vaccine efficacy 7 days or more after the second dose was 90.7%.


Join @Updates_in_Medicine Open / Comment

2022-01-05 04:46:22 ​​ Latest Guidelines on Diabetes
ADA (American Diabetes Association) 2022 standards of medical care


Join @Updates_in_Medicine Open / Comment

2022-01-03 05:25:34 ​​ Chlorthalidone for Hypertension in Advanced CKD

In this trial, patients with stage 4 chronic kidney disease and poorly controlled hypertension, as confirmed by 24-hour ambulatory blood-pressure monitoring, were randomly assigned to receive chlorthalidone (12.5 mg per day, with increases every 4 weeks if needed to a maximum dose of 50 mg per day) or placebo. Chlorthalidone therapy improved blood-pressure control at 12 weeks as compared with placebo.


Join @Updates_in_Medicine Open / Comment